Indivior settles patent dispute with Mylan over Suboxone.

Indivior has settled a patent dispute with Mylan related to generic versions of Suboxone, a treatment for opioid addiction. The settlement is confidential and does not affect the company's revenue, which is heavily reliant on Suboxone. The agreement resolves a long-standing legal battle between the two companies.

Indivior PLC, a global specialty pharmaceutical company, announced on September 25, 2017, that it had settled a patent dispute with Mylan Pharmaceuticals over generic versions of Suboxone, a treatment for opioid addiction [1]. The terms of the settlement, which resolved a long-standing legal battle between the two companies, are confidential.

The litigation, which had been pending in the U.S. District Court for the District of Delaware, resulted from Mylan's submission of an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) seeking approval to market generic versions of Suboxone Sublingual Film. Indivior's CEO, Shaun Thaxter, expressed his satisfaction with the settlement, stating that it reflected the company's commitment to protecting its intellectual property and creating certainty for Indivior [1].

Indivor is a leader in addiction treatment, with a 20-year legacy of advocacy and evidence-based treatment models [1]. The company's portfolio of opioid dependence treatments includes a strong pipeline of product candidates designed to expand its presence in this category and address other chronic conditions and co-occurring disorders of addiction [1].

The settlement does not affect Indivior's revenue, which is heavily reliant on Suboxone. In fact, the company recently received a new patent ('454) for Suboxone Film, further expanding its intellectual property estate for this product [1].

References:

[1] Indivior. (2017, September 25). Indivior enters into settlement with Mylan Pharmaceuticals. Retrieved from https://www.indivior.com/en/media/press-releases/indivior-enters-into-settlement-with-mylan-pharmaceuticals